Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Emmvee Photovoltaic IPO Review & Investor Guide

By Jagat Joshi
November 14, 2025

Emmvee Photovoltaic IPO will be open for Subscription on November 11, 2025, while the closing date is November 13, 2025. The Emmvee Photovoltaic IPO price band is set between ₹206 to ₹217 per share, with a face value of ₹2 each. As per the RHP, the company plans to raise around ₹2,900 crores through an Initial public offering (IPO).

It can be challenging for investors to decide if the Emmvee Photovoltaic IPO is a good investment. If you are unsure and still thinking about whether to apply or skip this IPO, don’t worry. This article presents the top key factors and a detailed review of the Emmvee Photovoltaic IPO. This will help you analyze the strengths, risks, and financial details of the company, improving your investment decision.

About Company

Incorporated in 2007, Emmvee Photovoltaic is a growing company involved in the manufacturing of integrated solar PV modules and cells. In fact, as of March 31, 2025, Emmvee Photovoltaic is one of the substantial solar PV module manufacturers in India in terms of production capacity.

The company’s portfolio consists of bifacial and mono-facial TOPCon modules and cells, and Mono PERC modules. The company has skilled and experienced promoters, who are a key factor in the company’s growth. Moreover, their strength is the second-largest company in India that manufactures both solar panels and solar cells. Moreover, the company has four factories on 22.44 acres in two locations in Karnataka. Their solar PV modules have received various international quality accreditations that demonstrate their reliability and durability.

Strengths

Emmvee Photovoltaic is the 2nd largest pure-play integrated solar PV module and cell manufacturer in India.

They are one of India’s largest solar module makers, known to offer high-quality products.

Its modern factories allow them to work efficiently in an eco-friendly way.

The firm consists of experienced Promoters, as well as a professional and experienced senior management team.

Over the last 3 years, the company has had a good ROE of 104.60%.

Weaknesses

The business is mainly dependent on a limited number of products. Meaning any reduction in the demand for these products can badly impact the business and its condition.

The company pays the import duties and faces limits on some raw materials from other countries. Any delay or shortage in the raw material can negatively impact the business and cash flow.

Emmvee buys some of its manufacturing equipment from other countries. If any problem occurs in getting equipment can affect the company and disturb the production.

Three months ending June 30, 2025, the company had negative cash flow from operations, and it can happen again in the future, which can affect the business and cash flow.

Emmvee Photovoltaic IPO Review

Reviewer	Recommendation
IPO Watch	May Apply
Kunvarji Finstock Pvt Ltd	Apply
Bajaj Financial Securities Limited	Not Rated
BP Equities (BP Wealth)	Apply
Canara Bank Securities Ltd	Apply
Capital Market	May Apply
Choice Equity Broking Pvt Ltd	Apply
GEPL Capital Ltd	Apply
IDBI Capital	Apply
Nirmal Bang	Apply
Reliance Securities	Apply
SBICAP Securities Limited	Apply
SMC Global	Neutral
SMIFS Limited	Apply
Sushil Finance Ltd	Apply
Swastika Investmart Ltd	Apply

Emmvee Photovoltaic IPO Details

IPO Open Date:	November 11, 2025
IPO Close Date:	November 13, 2025
Face Value:	₹2 Per Equity Share
IPO Price Band:	₹206 to ₹217 Per Share
Issue Size:	Approx ₹2,900 Crores
Fresh Issue:	₹2,143.86 crores
Offer-for-Sale:	up to 3,48,45,069 equity shares
Registrar	KFin Technologies Limited
IPO Lead Managers	JM Financial Ltd. IIFL Capital Services Ltd. Jefferies India Pvt. Ltd. Kotak Mahindra Capital Co. Ltd.
Basis of Allotment	November 14, 2025
IPO Listing Date:	November 18, 2025
Listing	BSE, NSE

Financial Performance Trend Details

Particulars	30 Jun 2025	31 Mar 2025	31 Mar 2024
Total income	₹1,042.22 Crores	₹2,360.33 Crores	₹954.44 Crores
EBITDA	₹347.38 Crores	₹721.94 Crores	₹120.44 Crores
Profit After Tax (PAT)	₹187.68 Crores	₹369.01 Crores	₹28.90 Crores
Net Worth	₹718.79 Crore	₹531.41 Crore	₹162.77 Crore
Total Borrowings	₹2,032.11 Crores	₹1,949.69 Crores	₹1,441.30 Crores

Key Indicators

KPI	Values
ROE	104.60%
ROCE	23.33%
Debt/Equity	3.63
Price to Book Value	24.25
Market Capitalization	₹15,023.89 Cr.
RoNW	-4.15%
EBITDA Margin	15.68%

Promoters & Track Records, if any

Manjunatha Donthi Venkatarathnaiah, born on August 8, 1967, aged 58 years, is one of the Promoters and is also the Chairman and Managing Director of the Company. He holds 285,988,995 equity shares, representing 48.18% of the paid-up Equity Share capital in the company.

Shubha Manjunatha Donthi, born on March 23, 1972, aged 53 years, is one of the Promoters and is also a non-executive director of the Company. She holds 285,989,000 equity shares, representing 48.18% of the paid-up Equity Share capital in the company.
Suhas Donthi Manjunatha, born on June 2, 1995, aged 30 years, is one of the Promoters and is also a whole-time director, President, and Chief Executive Officer of the Company. He holds 10,774,776 equity shares, representing 1.82% of the paid-up Equity Share capital in the company.

Sumanth Manjunatha Donthi, born on December 24, 2000, aged 24 years, is one of the Promoters and is also the Chief Strategy and Business Development Officer of the Company. He holds 10,774,776 equity shares, representing 1.82% of the paid-up Equity Share capital in the company.

Peer Comparison With the Company

Name of the Company	Face Value (₹)	Basic EPS (₹)	Diluted EPS(₹)	RONW (%)	P/E Ratio	NAV(₹)
Emmvee Photovoltaic Limited	2	6.22	6.22	69.44	[●]	8.95
Listed Peers
Waaree Energies Limited	10	68.24	67.96	20.34	50.47	329.9 6
Premier Energies Limited	1	21.35	21.35	33.21	51.30	62.61
Vikram Solar Limited	10	4.61	4.60	11.26	70.97	39.24
Saatvik Green Energy Limited	2	19.09	19.07	63.41	27.49	30.14
Websol Energy Systems Limited	10	36.66	36.17	55.65	33.83	65.88

Industry Peer Group P/E ratio

The Solar Energy industry peer group has a P/E ratio ranging from 27.49 to 70.97, with an average of 46.81.

Expansion

The proceeds raised from the fresh issue will be utilized towards the repayment/prepayment of existing borrowings taken by the company and its subsidiary’s along with the interest.

Lastly, the remaining funds will be used for the company’s general corporate purposes.

Emmvee Photovoltaic IPO – Should You Apply or Not?

Emmvee Photovoltaic offers strong industry growth due to the rising demand for solar energy, rapid financial growth, capacity expansion plans, and debt reduction to strengthen its balance sheet. But, high capital needs, global competition, negative cash flow, and dependence on policy support are key concerns.

As of November 8, the GMP of Emmvee Photovoltaic is ₹20, showcasing a potential listing of around 8%-11%. Short-term investors may consider applying for the listing gains due to the attractive GMP and strong brand recognition. And cautious investors must carefully analyze the company’s financial background, risks, strengths, and valuation concerns before subscribing.

Please note:

Investors are advised to make their own decisions and apply entirely at their own risk. This article is written using information from the company’s RHP (Red Herring Prospectus) data and online sources. If you have any queries, kindly contact the IPO Watch Team.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.